Based on result announced on 28.02.2020 for Q4, 2020 (Financial year ended 31.12.2019), the group cash and bank balance stood at RM11.6 mil which represents approx 10.6% with consistent dividend paid for the last two financial years ( that is 31.12.2018 and 31.12.2019) at RM0.01 sen per share. The average revenue per year under review was above RM85 mil generated and improved margin from 7.13% to 7.95% ( YE 31.12.2018 against 31.12.2019. With Covid 19 became imminent and part of society issues to deal with, hence those group that related to Medical supplies and manufacture will highly likely benefit from the outbreak in term of revenue and profit bearing in mind that once break even point achieved for company, the margin will likely to be handsomely rewarded in term of higher margin and absolute amount in term of profit after tax. With this background set, the group profit for Q 1, 2020 and beyond is likely to be bright. Right time To study on the Group.
Tp 1, O.80 cent achieved...... going to my 2nd TP 0.90 ... , as long as other Covid counter Fly, it will follow.. high demand on their product oso...... Qr je xtau bila kluar, kalau big profit....sure limit up.....
@ Chua Joe Beng: Donald Trump Is a business man not a real politic person. Whatever he has done is for $$$$ purpose. Hand Glove and Face mask are to wear together for every medical team for all kind of medical procedure. And for us, we do wear face mask but not all wear glove.....so, Mask demand should be good.But look at all the glove company share prices, all gone up very high. Do they not think that glove and mask are wearing together in every medical attention in clinic and hospital??? Why only glove company shares price up but not mask company? Or Maybe because Malaysia produce rubber ...............business from oversea .....??
Oceancash Pacific Bhd Maintain buy, we remain positive on Oceancash Pacific Bhd’s (OCP) business outlook after our recent meeting with its management. We continue to like OCP, considering the: i) favourable growth prospects in the non-woven hygiene segment; ii) steady contribution of foreign felt sales from Thailand and Indonesia; as well as iii) strong management team with in-depth technical know-how. At 10 times financial year 2020 estimated (FY20E) price-earnings ratio (PER) on the back of a projected earnings-per-share (EPS) growth of 33% for FY20E, OCP’s valuation looks appealing.
Prospects-wise, we believe the increasing contribution from Thailand and Indonesia (foreign felt sales accounted for about 61% of 9MFY19 insulation revenue) should be more than sufficient to cover for the expected shortfall in local felt sales (estimated 2020 total insured value forecasts lower by 1% to 590,000 units).
Elsewhere, construction of the felt production facility in Thailand remains on track to be completed by 2HFY20, and OCP is planning to relocate one of its two existing Malaysian production lines to tap the strong demand for resinated felt and increase utilisation of excess capacity (current utilisation rates: estimated 50%). Locally, we understand OCP has been supplying felt to Proton refreshed models (Saga, Iriz and Persona), and with this track record, the company is hopeful to participate in the Proton completely-knocked down (CKD) X50 supply chain moving forward. We think OCP may give the CKD X70 contract a miss due to unfavourable pricing, similar to our observation of other auto-parts players.
Meanwhile, we learnt that OCP recently increased hygiene’s production capacity to 600 tonnes per annum (+25% from 480 tonnes per annum) to cater for the growing demand of non-woven products for one of OCP’s major customer. We gather that this customer, one of the largest hygiene product companies in Asia, is setting up a regional hub in Malaysia, which bodes well for OCP’s hygiene long-term revenue growth.
We wait for all the heroes to join us here. As most of the Covid related shares out there was up to certain limit even the company are making loses at the previous years. Many people will do gathering over here.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
tuapuikia
2,346 posts
Posted by tuapuikia > 2020-06-01 09:48 | Report Abuse
hahahhahahaha